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Objective: The EUROSTAR (European Collaborators on Stent/graft techniques for aor-
tic aneurysm repair) Registry was established in 1996 to collect data on the outcome of
treatment of patients with infrarenal aortic aneurysms with endovascular repair. To date,
88 European centers of vascular surgery have contributed. The purpose of the study was
to evaluate the results of this treatment in the medium term (up to 4 years) according
to the analysis of “hard” or primary end points of rupture, late conversion, and death.
Patients and Methods: Patients with aortic aneurysms suitable for endovascular
aneurysm repair were notified to the EUROSTAR Data Registry Centre before treat-
ment to eliminate bias due to selective reporting. The following information was col-
lected on all patients: (1) demographic details and the anatomic characteristics of their
aneurysms, (2) details of the endovascular device used, (3) complications encountered
during the procedure and the immediate outcome, (4) results of contrast enhanced
computed tomographic imaging at 3, 6, 12, and 18 months after operation and at
yearly intervals thereafter, and (5) all adverse events. Life table analysis was performed
to determine the cumulative rates of (1) death from all causes, (2) rupture, and (3)
late conversion to open repair. Risk factors for rupture and late conversion were iden-
tified through regression analysis.
Results: By March 2000, 2464 patients had been registered, and their mean duration of
follow-up was 12.19 months (SD, 12.3 months). There were 14 patients with confirmed
rupture of their aneurysms. The cumulative rate (risk) of rupture was approximately 1%
per year. Emergency surgery was undertaken in 12 (86%) patients, of whom five (41.6%)
survived. Two patients who were not treated surgically also died, which resulted in an
overall death rate of 64.5% (9/14) of the patients. Significant risk factors for rupture
were proximal type I endoleak (P = .001), midgraft (type III) endoleak (P = .001), graft
migration (P = .001), and postoperative kinking of the endograft (P = .001). Forty-one
patients underwent late conversion to open repair with a perioperative mortality rate of
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24.4% (10/41). The cumulative rate (risk) of late conversion was approximately 2.1%
per year. Risk factors (indications) for late conversion were proximal type I endoleak (P
= .001), midgraft (type III) endoleak (P = .001), type II endoleak (P = .003), graft
migration (P = .001), graft kinking (P = .001), and distal type I endoleak (P = .001).
Conclusions: Endovascular repair of infrarenal aortic aneurysms with the first- and sec-
ond-generation devices that predominated in this study was associated with a risk of late
failure, according to an analysis of observed hard end points of 3% per year. Action taken
to address the risk factors identified by the study may improve results in the future. (J
Vasc Surg 2000;32:739-49.)
The feasibility of endovascular repair of abdomi-
nal aortic aneurysms and the short-term benefits of
this approach, in comparison to conventional open
surgery, are no longer in doubt. Subject to the vas-
cular anatomy being favorable, successful deploy-
ment of the endograft can be achieved in more than
97% of the patients with a 30-day death rate below
3% (operative death has been low despite a tenden-
cy to select patients with a relatively high incidence
of major comorbidities for this treatment).
The crucial and as yet unresolved issue with
respect to endovascular aneurysm repair is its effica-
cy in the long term. The primary objective of treat-
ment is to prevent the death of the patient from rup-
ture of the aneurysm. Therefore, rupture and death
from rupture are noncontentious primary or “hard”
end points for the evaluation of long-term results. A
requirement to undertake open surgery to replace
the endoluminal device with a conventionally
sutured graft, for whatever reason, is also unequivo-
cal evidence of failure of the endovascular procedure
and therefore a valid primary end point.
Analysis of the long-term results of endovascular
repair on the basis of these primary or hard end
points has not been possible previously because the
total number of patients available for study has been
relatively small and their duration of follow-up
short. Worldwide experience spans less than one
decade, and most patients with endografts have been
treated within the last year or two. For this reason,
considerable attention has been focused on sec-
ondary, surrogate, or “soft” end points, including
endoleak, persistent endoleak, secondary interven-
tion, and endotension as evidenced by postoperative
change in the size of the aneurysm sac.1-4 However,
evidence to confirm that any of these represents a
reliable indicator of the eventual outcome of treat-
ment is lacking.
This report from the EUROSTAR Organisation
has two important objectives: first, to present, for
the first time, an assessment of the results of
endovascular repair of abdominal aortic aneurysms
according to the analysis of hard end points and sec-
ond, to identify from the database significant risk
factors for the occurrence of these end points. It is
anticipated that these data together will provide a
valuable guide to actions that need to be taken to
secure improved results from endovascular treat-
ment of abdominal aortic aneurysms in the future.
METHODS
The EUROSTAR Project. The EUROSTAR
Project was launched in 1996 with the objective of
collating information on the results of endovascular
treatment of abdominal aortic aneurysms. Because
the efficacy of the new technology of intra-aortic
stent grafting was and remains unproved, it was con-
sidered essential to recruit as many patients as possi-
ble as quickly as possible to develop a database large
enough to allow conclusions to be drawn within the
shortest time possible. Achievement of this objective
necessitated a large-scale multicentered internation-
al study. In most European countries, access to
endovascular devices has been less restricted than in
other parts of the world, most notably the United
States, and for this reason Europe represented a very
suitable setting for such a study. By March 2000,
physicians from 88 centers in 16 European countries
had registered 2464 patients. There is an expecta-
tion that participating centers will include all eligible
patients. For any bias due to selective reporting to
be eliminated, the study protocol requires that
patients should be notified to the Data Registry
Centre at least 24 hours before their operation. This
ensures that the decision to register a patient is not
influenced by the outcome of the procedure itself. A
policy of excluding from the Registry all patients
from centers who consistently fail to deliver follow-
up data according to minimum standards of timing
and quality has resulted in near complete submission
of follow-up information. The number of censored
observations provided in Tables II and IV includes
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all the patients whose data have not been entered
onto the database at the time of analysis because of
an inevitable lag in collection and entry. Eventual
data collection is nearly complete.
Patients. At the end of March 2000, the total
cohort of 2464 patients included 2267 men and
197 women (male-female ratio, 11.5:1). Their mean
age was 70.5 years (range, 37-93 years). The opera-
tive risk profile of the patients according to the
American Society of Anesthesiologists (ASA) classi-
fication included ASA 1 in 203 patients (8.2%); ASA
2 in 875 (35.5%); ASA 3 in 1083 (43.9%), and ASA
4 in 170 (6.9%). The ASA grade was not recorded
in 133 patients (5.3%). The risk scores of The
Society for Vascular Surgery and The International
Society for Cardiovascular Surgery,5 identified
smoking, hypertension, and cardiac disease as the
most prevalent risk factors. Six hundred fifty-two
patients had undergone previous laparotomy, and
320 patients were considered to be unfit for con-
ventional open surgery, of whom 98 were consid-
ered to be unfit for general anaesthesia.
Cardiorespiratory compromise has been the most
frequently stated reason for unfitness.
Aneurysms. Contrast enhanced computed
tomographic (CT) scanning (2207 patients) com-
bined with calibrated angiography (2081 patients)
was the method of choice for preoperative assess-
ment in most centers. Preoperative intravascular
ultrasound scan examination was performed in 10
patients. The mean maximal transverse diameter of
the aneurysms was 56.53 mm (range, 18-150 mm).
The mean of the aneurysms’ neck diameters was
22.45 mm (range, 11-35 mm), and the mean neck
length was 27.7 mm (range, 5-110 mm). There
were associated aneurysms of the common iliac
arteries in 35% of the patients.
Endovascular devices. Only devices with
European regulatory approval (CE mark) were eligi-
ble for inclusion in the study. Bifurcated endovascu-
lar stent-grafts were used in 2261 patients (92%).
The make and manufacturer of each device in
patients who survived more than 30 days are shown
in Table I. This table also shows the mean duration
of follow-up of each device. The mean duration was
determined by the date of introduction of the prod-
uct into the EUROSTAR study, and that was deter-
mined by the date that it received regulatory
approval for use in European hospitals.
Patient follow-up. Patients were assessed
through clinical observation and with contrast-
enhanced CT scans at 1, 3, 6, 12, and 18 months
after the operation and at yearly intervals thereafter.
Color duplex ultrasound scan examination with or
without contrast enhancement was also undertaken
in a number of centers. According to the original
study protocol, aortography was mandatory at 12
months, but subsequently, this investigation was
undertaken only when indicated by the results of CT
imaging, at the discretion of the responsible physi-
cian. Data reported to the Data Registry Centre
included all adverse events. An indication of the
completeness of the data can be obtained from the
number of censored observations in the graph show-
Fig 1. Life table analysis of overall survival.
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ing overall survival (eg, at 1 year the ratio of actual
to expected observations was 77.2% [1196/1549]
and at 2 years 73.7% (564/765]). The purpose here
is to report the incidence of the following: (1) the
results of treatment to 30 days, (2) death from all
causes and sudden death of unknown cause that
occurred more than 30 days after operation, (3)
rupture of the aneurysm and the outcome from this
event, (4) risk factors for late rupture of the
aneurysm, (5) conversion to open repair of the
aneurysm undertaken more than 30 days after oper-
ation and the outcome, and (6) risk factors for late
conversion to open repair.
Statistical analysis. Crude risk ratios with 95%
CIs were calculated to quantify the correlation
between procedural complications and potential risk
factors. A regression analysis that was based on the
Cox proportional hazards model was constructed
with factors known to be associated with the occur-
rence of conversion and rupture. The patients with
endovascular stent-grafts who survived 30 days were
included in the risk factor analysis. Because of the
small number of patients with a rupture and late
conversion, only a univariate regression analysis was
performed. The potential risk factors that we
assessed were stent-graft kinking, migration, steno-
sis, thrombosis, and all types of endoleak. No other
risk factors were analyzed. Survival analysis was cal-
culated with Kaplan-Meier testing. All statistical
analyses were performed with SAS software (version
6.12; SAS Institute, Inc, Cary, NY).
RESULTS
Outcome of operative procedures: results to 30
days
Deployment of the endoluminal device was
achieved successfully in all but 60 of 2464 patients
(97.6%). Conversion to open repair was undertaken
at the time of the initial procedure in 34 patients
(1.3%). There was one rupture within the first 30
days. This patient immediately underwent an open
repair. However, the patient died. There were 79
deaths in the first postoperative month, which result-
ed in a 30-day death rate of 3.2%. The operative
death rate for patients in ASA class 4 was 11.8% (20/
170), compared with 3.4% for ASA class 3 patients
(37/1083), 1.7% for ASA class 2 patients (15/875),
and 1.5% for ASA class 1 patients (3/203) (P <
.001), which indicated that death was related primar-
ily to comorbidity. An endoleak was identified on the
completion angiogram in 419 of 2404 of the patients
who underwent a successful deployment. At 1
month, an endoleak was present in 140 (8.3%) of
1688 patients.
Follow-up: outcome events occurring more than
30 days after operation
Death from all causes and sudden death of
unknown cause. After endovascular repair of their
aneurysms, 136 patients died between 1 and 48
months. Life table analysis of survival for the whole
cohort of EUROSTAR patients is shown in Fig 1.
Fig 2. Life table analysis of freedom from late conversion among survivors.
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The number of patients expected at each follow-up,
the number of censored observations, and the SEs at
each point are shown in Table II. It was possible to
attribute a precise cause of death in 113 patients. In
13 patients the cause of death was unrecorded. This
group includes 10 patients in whom sudden death
from rupture of their aneurysms cannot be excluded.
Rupture of the aneurysm. Thirteen patients
had rupture of a treated aneurysm 30 days or more
after operation. Only those patients with unequiv-
ocal evidence of rupture that was based on the
findings at operation, CT images, or the results of
postmortem examination have been included in
this analysis. Patients who collapsed and died sud-
denly without a precise diagnosis having been con-
firmed (10 patients) were not included. Details of
the patients with proved rupture are shown in
Table III. The peak incidence of rupture occurred
18 months after operation (range, 0-24 months).
The annual cumulative rate approximates to 1%
(1.4% in the first year, 0.6% in the second year).
Emergency open surgery was undertaken in 12
patients (85.7%); five patients (41.6%) survived.
There were no survivors among the patients who
were not subjected to an emergency operation.
The overall death rate due to late rupture (> 30
days) of the aneurysm after endovascular repair was
69.2% (9/13) of the patients.
Risk factors for aneurysm rupture. Significant
risk factors for postoperative late rupture (> 30 days)
as obtained with univariate analysis of the data are
shown in Table IV. Primary data on the incidence of
the risk factors are also included in this table.
Conversion to open repair. During follow-up,
the decision to remove and replace an endovascular
device with a conventionally sutured graft was made
at the discretion of the responsible physician. To
date, 41 of these procedures have been undertaken
within the EUROSTAR cohort of patients (Table
V). Conversion has never been undertaken solely at
a patient’s request in the absence of an evidence of
failure of treatment. The peak incidence of conver-
sion, at the time of analysis, occurred at 18 months
(range, 1-48 months). Life table analysis of the rate
of late conversion to open repair is shown in Fig 2.
The number of patients expected, the SE, and the
number of censored observations are shown in Table
VI. The average annual risk of conversion approxi-
mates 2.1%. The risk increased with time after oper-
ation (1% in the first year, 3.7% in the second year).
There were 10 deaths within 30 days of the proce-
dure, which resulted in a death rate of 24.4%.
Risk factors (indications) for conversion to
open repair. Risk factors for late conversion to open
repair that were revealed through univariate analysis
are shown in Table VII. These may be considered
Table I. Endovascular devices and their duration of follow-up
Device No. of patients Mean follow-up (mo) SD of follow-up
Stentor (Mintec, La Ciotat, France) 293 27.93 17.15
Vanguard (Boston Scientific/Meadox Medical Oakland, NJ) 857 14.82 9.84
AneuRx (Medtronic, Sunnyvale, Calif) 430 8.60 7.87
Talent (World Medical, Sunrise, Fla) 308 7.63 8.10
Zenith (Cook, Indianapolis, Ind) 192 3.53 3.93
Ancure (Endovascular Technologies, Menlo Park, Calif) 106 15.42 13.08
Excluder (WL Gore, Flagstaff, Ariz) 88 2.40 2.60
Other 51
Table II. Data of life table analysis of overall survival
Time (mo) Censored observations No. of patients at risk Total no. of deaths Survival (%) SE
0 2464
l 337 2048 79 96.6 0.00374
3 155 1861 111 95.0 0.00466
6 258 1571 143 93.10 0.0690
12 353 1196 165 91.42 0.00658
18 399 781 181 89.58 0.00789
24 201 564 197 87.11 0.00980
36 337 216 208 82.89 0.0155
48 142 67 215 75.05 0.0315
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indications for conversion rather than risk factors.
Data of the incidence of the risk factors are also
shown in this table.
DISCUSSION
The first successful procedure6 established the
feasibility of endovascular aneurysm repair and,
given the associated advantages of minimally inva-
sive surgery over the conventional operation for this
condition, ignited considerable enthusiasm for it
among vascular physicians, the vascular devices
industry, and patients. In recognition of the need to
temper enthusiasm for this exciting new technology
with responsible evaluation of the risks, as well as
the benefits, the EUROSTAR Registry program was
launched in 1996. The objective was to establish a
database of sufficient size and quality to allow scien-
tifically valid evaluation not only of the procedures
themselves,7 but also of the long-term risks and
durability of aneurysm repair by this method. The
early results of treatment in the EUROSTAR cohort
of patients have been reported previously1 and are
presented here in summary only. In common with
other similar reports, successful deployment of the
endovascular device was achieved with a very high
degree of consistency (in 97.6% of patients) and a
low incidence of serious complications. The periop-
erative death rate was 3.2% (79/2464), and this
compares well with the reported results of open
surgery. The cumulative survival rate at 48 months
for the whole cohort of patients was 75%. In most
cases, death was not directly related to the
aneurysm, and as an outcome measure of treatment
for this condition, death from all causes is clearly too
crude to be of any value, especially without reference
to a scientifically valid comparator.
Previous reports on the longer-term results of
treatment of infrarenal aortic aneurysms with intralu-
minal endografts have been based on relatively small
numbers of patients with a short duration of follow-
Table III. Details of patients with a proved rupture of the treated aneurysm
Serial no. Time since operation (mo) Intervention on rupture Device Outcome (at 30 d)
1 18 Conversion Vanguard* Death
2 24 Conversion Vanguard* Death
3 3 Conversion AneuRx Death
4 12 Conversion Stentor* Survived
5 18 Conversion Stentor* Survived
6 6 Conversion Vanguard* Death
7 18 Conversion Vanguard* Survived
8 18 Nil Vanguard* Death
9 6 Conversion Vanguard* Survived
10 24 Conversion Vanguard* Death
11 3 Nil Talent Death
12 18 Conversion Vanguard* Death
13 24 Conversion Vanguard* Survived
14† 0 Conversion Talent Death
*Discontinued model devices.
†One rupture within 30 days of endovascular repair.
Table IV. Risk factors for late rupture and their incidence after endovascular repair
Free from rupture Rupture Rupture free Adverse factor 
and adverse with adverse from adverse free from Relative hazard 
Adverse factor factor (n) factor (n) factor (n) rupture (n) P value ratio (95% CI)
Proximal type I endoleak 2250 3 10 62 .001 7.59 (2.09-27.62)
Midgraft (type III) endoleak 2224 5 8 88 .001 8.95 (2.92-27.52)
Stent-graft migration 2248 3 10 64 .001 4.53 (1.24-16.66)
Kinked endograft 2216 3 10 96 .001 3.13 (1.40-11.49)
Type II endoleak* 2106 2 11 206 .415*
Distal type I endoleak* 2177 1 12 135 .776*
Endograft stenosis* 2275 0 13 37 .646*
Thrombosed endograft* 2235 0 13 77 .503*
*Statistically not significant.
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up.8-11 This reflects the limited total world experi-
ence of these techniques spanning less than one
decade, the last few years of which have accounted
for most of the operations. In the absence of suffi-
cient data on primary or hard end points for mean-
ingful analysis of results beyond the immediate post-
operative period, attempts have been made to predict
the eventual outcome of the procedures through
extrapolation from surrogate or soft end points.
Attention has been focused mainly on endoleak
as an indicator of an unsuccessful operation.12 The
EUROSTAR Organisation itself has proposed sur-
vival free from persistent endoleak as a possible out-
come measure.1 The rationale for using endoleak as
an indicator of failure of treatment is based on an
assumption that in the presence of endoleak,
aneurysms will continue to expand and eventually
rupture. However, recent studies have shown that
the correlation between the presence or absence of
endoleak and postoperative change in the morphol-
ogy of the aneurysm sac is poor.13 Furthermore,
there are anecdotal reports of rupture of aneurysms
after endovascular repair without detectable
endoleak. The Laplace principle tells us that it is
pressure or “endotension”,14,15 rather than flow
within the aneurysm sac, that causes it to expand
and rupture. Endotension may be present in the
absence of detectable flow.16 Unfortunately, direct
measurement of endotension is not yet possible.
However, continued expansion or reexpansion of
the sac postoperatively is a sure indication of its pres-
ence and, therefore, a strong indication for sec-
ondary intervention.
Secondary intervention has also been proposed as
an outcome measure. It is suggested that results
should be reported in terms of both survival and sur-
vival free from secondary intervention in a way that is
analogous to primary and secondary patency of arter-
ial bypass grafts for occlusive arterial disease.
Although this idea clearly has considerable merit, its
value as an indicator of the final or definitive outcome
of operation is undermined by a lack of consensus on
the question of what constitutes an appropriate indi-
cation for secondary intervention. It cannot be
assumed that failure to achieve the primary objective
of treatment (ie, prevention of death from rupture of
the aneurysm) would have resulted in every case if
secondary intervention had not been undertaken.
Rupture of the aneurysm, death from rupture,
and conversion to open repair are unequivocal indi-
cators of failure of treatment. With 2464 patients
entered on the database and a follow-up period
extending to 4 years, for the first time, the
Table V. Details of patients who underwent late
conversion after endovascular aneurysm repair
Time since 
operation Indication Outcome
Serial no. (mo) for conversion (at 30 d)
1 24 Limbs occluded Survived
2 18 Rupture Death
3 36 Migration Survived
4 36 Graft dislocation Survived
5 24 Rupture Death
6 12 Endoleak + graft stenosis Survived
7 3 Rupture Death
8 36 Painful enlarging aneurysm Death
9 36 Endoleak + migration Survived
10 24 Endoleak Survived
11 36 Increasing endoleak Survived
12 12 Rupture Survived
13 18 Rupture Survived
14 6 Rupture Death
15 36 Graft thrombosis Survived
16 48 Graft thrombosis Death
17 36 Endoleak Survived
18 6 Persistent endoleak Survived
19 18 Migration + graft stenosis Survived
20 24 Kinking + graft migration Survived
21 18 Rupture Survived
22 18 Stent breakage Survived
23 6 Rupture Survived
24 18 Prosthesis tear + endoleak Survived
25 24 Rupture Death
26 18 Migration Survived
27 6 Endoleak + graft thrombosis Survived
28 3 Painful aneurysm Survived
29 18 Rupture Death
30 3 Suspected rupture Death
31 48 Migration Survived
32 18 Migration Survived
33 24 Rupture Survived
34 36 Endoleak Death
35 60 Endoleak Survived
36 60 Migration Survived
37 12 Increasing endoleak Survived
38 3 Endoleak Survived
39 6 Endoleak Survived
40 2 Endoleak Survived
41 6 Endoleak Survived
EUROSTAR collaborators are in a position to
report on the medium- to late-term results of
endovascular aneurysm repair that are based on the
analysis of these hard end points. Because the aim of
the study was to present intermediate- to late-term
results, the risk factor analyses presented here have
included only those patients who were alive free
from conversion at 30 days after endovascular repair.
However, an analysis (not presented here) that
included all patients on the “intention-to-treat”
principle revealed the same factors to be significant.
Multivariate analysis that could confirm indepen-
dence of the risk factors is not yet possible because
the number of ruptures is too small. However, uni-
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variate analysis was used to confirm statistically sig-
nificant association. When these results are evaluat-
ed, it is important to take account of the fact that,
inevitably, they mainly reflect the outcome of treat-
ment with the earliest generations of endovascular
device and especially those associated with Vanguard
I and II (Boston Scientific Corporation/Meadox
Medical, Oakland, NJ). It is possible that the newer
generations of endograft will perform differently,
but this remains to be proved.
Lumsden et al17 first reported that some risk of
rupture may persist after endovascular aneurysm
repair. It is now possible, for the first time, to quan-
tify this risk. Fourteen patients who registered with
EUROSTAR had unequivocal evidence of rupture
of their aneurysm at intervals from 1 to 24 months
after operation (mean, 14 months). Another 10
patients died suddenly of unknown causes. At least
three of these patients had aneurysms with a maxi-
mal diameter in excess of 6 cm shortly before their
death. Although cardiac malfunction and other caus-
es are possible, rupture of the aneurysm is likely to
account for some of these 10 deaths. If only those
patients in whom the diagnosis was confirmed are
taken into account, the cumulative rupture rate, cal-
culated with life table analysis, approximates to 1.0%
per year. However, should one also speculatively
take into account those patients who died suddenly
of unconfirmed causes in whom rupture is a possi-
bility, the risk of rupture increases to 1.7% per year.
It has been previously reported that rupture after
endovascular aneurysm repair is associated with a
lower death risk than might be expected other-
wise.18 In the current small series of 12 patients who
underwent emergency open repair after rupture, five
(41.6%) survived. Another two patients who were
not operated on died, which resulted in an overall
death rate of 64.3% (9/14), which is in line with
usual expectations after rupture of an abdominal
aortic aneurysm.19 The reasons for the two patients
not receiving an operation in the presence of known
rupture were not included in the database.
The numbers of different makes of stent-grafts
associated with rupture (Table III) reflect their rela-
tive proportion of use and the duration of follow-up.
It is not possible to draw any conclusions or compar-
isons regarding the performance of different makes
of devices in relation to rupture from this study.
Table VI. Life table data of late conversion
Total no. of Freedom from late 
Time (mo) Censored observations No. of patients at risk late conversion conversion among survivors SE
1 2325
3 339 1871 4 99.79 0.001
6 248 1586 9 99.47 0.001
12 353 1206 14 99.06 0.002
18 396 783 25 97.69 0.004
24 189 573 30 96.84 0.006
36 335 221 36 94.29 0.01
48 140 71 39 90.46 0.02
60 14 41 79.15 0.07
Table VII. Risk factors (indications) for late conversion and their incidence after endovascular repair
Late conversion Adverse 
Free from late Late conversion from  free factor free 
conversion and with adverse adverse factor from late Relative hazard 
Adverse factor adverse factor (n) factor (n) (n) conversion P value ratio (95% CI)
Proximal type I endoleak 2231 12 29 53 .001 19.39 (4.78-18.48)
Midgraft (type III) endoleak 2204 13 28 80 .001 4.87 (2.49-9.6)
Type II endoleak 2085 9 32 199 .003 2.63 (1.25-5.54)
Distal type I endoleak 2159 11 30 125 .001 2.61 (1.29-5.28)
Stent-graft migration 2229 12 29 55 .001 5.09 (2.54-10.11)
Kinked endograft 2194 9 32 90 .001 2.97 (1.4-6.28)
Thrombosed endograft* 2210 3 38 74 .148*
Stenosed endograft* 2248 1 36 40 .662*
*Statistically not significant. 
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The analysis of risk factors for postoperative rup-
ture, in this series, confirms the major importance of
proximal fixation site endoleak and the imperative of
secondary intervention, either endovascular or open,
to correct this problem. By contrast, distal fixation
site endoleak did not have a significant impact on the
risk of rupture. It is possible that distal endoleaks are
inherently less dangerous, perhaps because they tend
to be associated with lower pressure or endotension
within the sac of the aneurysm. A more likely expla-
nation is that most of the endoleaks that develop at
this site are resolved, soon after detection, with rela-
tively minor secondary endovascular procedures. On
the other hand, proximal fixation site endoleaks are
comparatively difficult to treat.
From the inception of endovascular aneurysm
repair there has been controversy about the manage-
ment of patent lumbar and inferior mesenteric arter-
ies arising from the sac. Oversewing of these vessels is
an integral part of conventional open surgery for this
condition, but most physicians have chosen not to
attempt intraluminal coiling or other techniques to
occlude them as a routine part of endovascular treat-
ment. Although type II endoleaks20 due to perfusion
of the sac from these vessels are seen in 10% to 20%
of patients, most resolve spontaneously, and many
physicians do not consider them to be of critical
importance. In this study there was a trend toward an
association between type II endoleak and rupture of
the aneurysm, although this just failed to reach statis-
tical significance. These results would seem to con-
firm that type II endoleaks are less important than
type I. However, in this study, reliance on these data
should be tempered with a degree of uncertainty
regarding the accuracy of diagnosis of type II
endoleak, in the absence of verification by a “core lab-
oratory.” One intriguing possibility is that a persistent
type II endoleak may be a “marker” for a concealed
type I endoleak. Kinking of intra-aneurysmal stent-
grafts results from contraction of the sac in its longi-
tudinal dimension after its effective exclusion from
arterial pressure21 and radial forces generated by
blood flowing through curved or angulated grafts.
Distal fixation site endoleak and midgraft endoleak
due to disassociation of the components of modular
devices may arise because of this phenomenon. The
direct relationship between kinking of the device and
the risk of eventual rupture of the aneurysm reported
here emphasizes the importance of this problem.
Future generations of endovascular stent-grafts for
aneurysm repair should be kink resistant. Stent migra-
tion is also a device-related issue that has been shown
in this study to be significantly associated with rup-
ture of the aneurysm and which similarly requires to
be addressed by appropriate improvements in the
design of endoluminal stent-grafts.
The conversion to open repair of an aneurysm
previously treated with endovascular repair is a seri-
ous undertaking. In the EUROSTAR series, this
procedure was undertaken in 41 patients. The peak
incidence of this event occurred at 18 months. The
average cumulative rate of conversion was 2.1% per
year. Because conversion to open repair is undertak-
en as a result of a decision made by the responsible
physician, risk factors in this case may be regarded as
indications. Endoleak of all types, including sac per-
fusion from patent aortic side branches, was the
main indication for conversion. Proximal fixation
site endoleak that cannot be resolved by other means
is universally acknowledged to be a compelling indi-
cation for conversion. Its strong association with
rupture and conversion in this study confirms the
appropriateness of this approach. However, it is not
universally accepted that endoleak from other sites
necessarily warrants conversion. Conventional wis-
dom currently dictates that type II endoleaks, in par-
ticular, do not justify conversion unless there also is
evidence of continuing expansion of the aneurysm
sac, although in this study, there was a significant
association between type II endoleak and conver-
sion. Recognition of the importance of endotension
has convinced many physicians that continuing or
renewed expansion of the aneurysm mandates con-
version regardless of the presence or absence of a
detectable endoleak. Unfortunately, it has not been
possible to assess this as a risk factor in the current
study. Another indication for conversion to open
repair was the migration of the stent, an important
cause of proximal fixation site endoleak.
Surprisingly, thrombosis of one or both limbs of the
endograft was not significantly associated with late
conversion. Common sense would suggest that graft
thrombosis should be a risk factor for conversion,
but it is possible that more often it has been dealt
with by other means, such as crossover bypass graft.
Twelve of the operations were undertaken for estab-
lished rupture of the aneurysm, with a successful
outcome in five.
The death rate associated with all operations for
conversion to open repair was 24.4%. This is approx-
imately six times higher than that associated with pri-
mary open repair of an abdominal aortic aneurysm.
Therefore, it is not a procedure to be undertaken
lightly. The responsible physician must be convinced
that the risk of rupture of the aneurysm or other life-
or limb-threatening disaster, is substantially greater
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than the risk of conversion before recommending
this course of action to his patient.
Recently, the Food and Drug Administration has
approved two endovascular devices intended for aortic
aneurysm repair for general use in the United States:
Ancure (Endovascular Technologies, Menlo Park,
Calif) and AneuRx (Medtronic, Sunnyvale, Calif).
This decision was based on convincing evidence of
acceptable short-term efficacy. However, the long-
term benefits and durability of the generic endovascu-
lar approach for the treatment of aortic aneurysms
have yet to be proved. The current results show that
the combined cumulative risk of potentially fatal
adverse events associated with early generations of
commercially available endovascular devices approxi-
mates to 3% per year. Properly structured randomized
trials are needed to determine how this compares with
the outcome after conventional open repair. However,
experience and published results have shown that
most physicians would probably anticipate a lower rate
of delayed life-threatening complications related
directly to the open operation.22 It is acknowledged
that the results of endovascular aneurysm repair may
improve as the relevant endovascular technologies
evolve in the light of experience. Until the long-term
efficacy of this approach has been established through
further analysis of reliable hard end points, caution
should be exercised with respect to its application in
routine clinical practice.
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